Canaccord Genuity Rates Intellia Therapeutics (NTLA) buy

Canaccord Genuity maintains a positive outlook on Intellia Therapeutics with a $49 target, a 209.34% upside from the current price.

By EarningsIQ Research Desk · Published Jun 16, 2026, 12:01 PM EDT · Updated Jun 23, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Canaccord Genuity rated Intellia Therapeutics, Inc. ($NTLA) "buy" with a $49 price target on June 16, 2026.

Since the rating, $NTLA is up 4.8% after 1 week, down 18.5% after 1 month and down 21.5% to date (from the $14.55 close on Jun 16, 2026).

NTLA Intellia Therapeutics, Inc.

$11.42 +24.00% year to date

Daily close · Oct 16, 2026

Key Points

Canaccord Genuity reiterated its buy rating on Intellia Therapeutics, setting a $49 price target on June 16, 2026.
Canaccord Genuity's $49 price target implies 209.34% upside from Intellia Therapeutics, Inc.'s ($NTLA) current $15.84 share price.
Intellia Therapeutics, a biotechnology company, has a market cap of about $2.08 billion and a negative forward P/E due to lack of profitability.
Key insiders, including Fred Cohen and William Chase, bought shares in early June, reflecting confidence in the company's prospects.

Get $NTLA trade alerts by text

We text you when insiders, Congress or big funds trade $NTLA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Intellia Therapeutics, Inc. alert may contain errors. Disclosures

Canaccord Genuity has reaffirmed its buy rating on Intellia Therapeutics, Inc. (NasdaqGM: NTLA) with a price target of $49. This rating was reiterated by analyst Whitney Ijem on June 16, 2026. The stock was recently trading at $14.92.

Intellia Therapeutics, Inc. Stock Up 30.5%

Shares of NasdaqGM:NTLA traded near $14.92. Intellia Therapeutics has a market cap of approximately $2.08 billion and a beta of 1.815, indicating higher volatility compared to the market. The stock's 52-week range is between $7.95 and $28.25, with a 50-day moving average of $13.66 and a 200-day moving average of $13.41. The company has a strong current ratio of 6.10, suggesting good short-term financial health, and a quick ratio of 5.04.

12-month forecast

$NTLA price target

Intellia Therapeutics, Inc. daily closes and this analyst's $49 target. Not advice.

Recent Earnings

In its latest earnings report, Intellia Therapeutics recorded revenue of $66.1 million, though it faced a revenue decline of 9.5%. The company is not currently profitable, with a negative return on equity of -56.3%. The next earnings report is expected on August 6, 2026.

Insider Buying and Selling at Intellia Therapeutics, Inc.

Several insiders at Intellia Therapeutics made notable purchases on June 9, 2026. Fred Cohen, William Chase, and Georgia Keresty each acquired 13,300 shares, while Brian Goff and Muna Bhanji purchased 9,200 shares each. These transactions were not part of a pre-planned trading program, indicating direct insider confidence in the company's future.

Analysts Set New Price Targets

On June 16, 2026, Canaccord Genuity maintained its buy rating for Intellia Therapeutics with a $49 price target. Previously, on June 15, Citizens reiterated a buy rating with a $30 target, and Wedbush reiterated a hold rating with a $12 target. The consensus among 19 analysts is a buy rating, with an average target price of $26.63.

About Intellia Therapeutics

Intellia Therapeutics, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts. It focuses on developing treatments using CRISPR/Cas9 genome editing technology. The company is working on therapies for transthyretin amyloidosis, hereditary angioedema, and other diseases. Led by CEO Dr. John M. Leonard, Intellia collaborates with several partners to advance gene editing applications.

Bottom Line

Canaccord Genuity's reaffirmation of a buy rating and a $49 target for Intellia Therapeutics highlights continued confidence in the company's potential. Investors often track analyst ratings as they can influence stock movements. It's important to remember that analyst ratings are forward-looking assessments and may not reflect current market conditions.